Amarin Corp

Most Recent

  • Amarin Stock Looks Like a Good Buy for Investors
    Healthcare

    Amarin Expects More Growth in 2021, Stock Looks Like a Buy

    By Ambrish Shah
  • vascepa hearing amarin stock
    Healthcare

    Amarin Stock Drops After Vascepa Appeal Hearing

    By Ambrish Shah
  • uploads///michele blackwell przZDqzZKpk unsplash
    Company & Industry Overviews

    How Much Higher Can Amarin Stock Surge?

    In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.

    By Oleksandr Pylypenko
  • uploads///biopharmaceutical
    Company & Industry Overviews

    Amarin Stock Crashes as FDA Plans Panel Review

    Yesterday, Amarin announced its receipt of a notice from the FDA about the agency’s plans for an advisory committee meeting on November 14.

    By Margaret Patrick
  • uploads///AdobeStock_
    Earnings Report

    Amarin’s Q2 Earnings and Robust 2019 Outlook

    Amarin Corporation (AMRN) reported its Q2 2019 earnings yesterday. Here’s how the stock, investors, and peer pharma stocks reacted.

    By Sushree Mohanty
  • uploads///girl _
    Company & Industry Overviews

    Amarin Stock Rises on Updated Fiscal 2019 Guidance

    Yesterday, Amarin (AMRN) revised its 2019 revenue guidance upwards from $350 million to $380 million–$420 million due to higher-than-anticipated demand for Vascepa in the first half of 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Label Expansion to Boost Revenue Growth for Amarin’s Vascepa

    On March 28, Amarin (AMRN) issued a press release announcing the submission of an sNDA (supplemental new drug application) to the FDA seeking label expansion for Vascepa.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Comparing Revenue Growth Trends for AMRN and IOVA

    In its first-quarter earnings conference call, Amarin (AMRN) reiterated its fiscal 2019 net revenue guidance of $350 million, which represents a YoY rise of more than 50%.

    By Margaret Patrick
  • uploads///fish oil _
    Company & Industry Overviews

    What Are Analysts Recommending for AMRN and IOVA in May?

    The consensus recommendation for Amarin in May is a “strong buy,” while the consensus recommendation for Iovance Biotherapeutics is a “buy.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Comparing Sangamo’s and Amarin’s Revenue Growth

    Sangamo is conducting Phase 1/2 studies on SB-318 and SB-913 for treating MPS (mucopolysaccharidosis) I and MPS II inherited metabolic disorders, respectively.

    By Margaret Patrick
  • uploads///blister _
    Company & Industry Overviews

    Analysts’ Recommendations for Sangamo Therapeutics and Amarin

    On April 5, Sangamo Therapeutics (SGMO) closed at $12.58, 3.62% above its previous closing price, 100.96% above its 52-week low of $6.26, and 38.78% below its 52-week high of $20.55.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Sarepta or Amarin: Who Is Controlling Expenses Better?

    Amarin is expected to dedicate a much higher percentage of its total sales to SG&A but a lower percentage of its total sales to R&D activities as compared to Sarepta Therapeutics from fiscal 2019 to fiscal 2021.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Sarepta or Amarin: Who’s Expected to Post Faster Revenue Growth?

    Wall Street analysts have projected Sarepta Therapeutics’ revenues to be $395.55 million, $611.37 million, and $1101.00 million, for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    How Amarin’s Expenses Are Evolving in Fiscal 2019

    In fiscal 2018, Amarin (AMRN) reported SG&A expenses of $227.0 million, a year-over-year rise of 69%.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Vascepa Demand Drove Amarin’s Revenue in Fiscal 2018

    In fiscal 2018, Amarin (AMRN) reported revenues of $229.2 million, a year-over-year rise of 27%, mainly driven by rising demand for Vascepa.

    By Margaret Patrick
  • uploads///pills _
    Earnings Report

    What Wall Street Recommends for Amarin after Q4 2018 Results

    On February 27, Amarin (AMRN) closed at $21.18, 5.85% higher than its previous closing price, 801.28% higher than its 52-week low of $2.35, and 9.24% below its 52-week high of $23.33.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Amarin or Novavax: Who’s Controlling Expenses Better?

    In its investor presentation, Amarin (AMRN) highlighted the United States as its priority target market for commercializing Vascepa.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Amarin or Novavax: Which Will Report Faster EPS Growth?

    In its investor presentation, Amarin (AMRN) highlighted the annual death toll attributable to cardiovascular disease in the United States to more than 800,000 while the yearly treatment cost is estimated at $555 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Amarin or Novavax: Which Will Report Faster Revenue Growth?

    With its 2018 unaudited results, as announced in an investor presentation, Amarin (AMRN) has guided for net total revenue in the range of $72 million–$76 million…

    By Margaret Patrick
  • uploads///fish oil _
    Company & Industry Overviews

    What Wall Street Recommends for Amarin and Novavax

    On February 22, Amarin (AMRN) closed at $19.87, 14% higher than its previous closing price and 746% higher than its 52-week low of $2.35.

    By Margaret Patrick
  • uploads///pill _
    Healthcare

    Why Ligand Pharmaceuticals Tanked 25%

    Today, US pharmaceutical firm Ligand Pharmaceuticals (LGND) fell 25% from yesterday’s closing price to a low of $98.86 for the day.

    By Jitendra Parashar
  • uploads///euro _
    Company & Industry Overviews

    Why Amarin Is Soaring in First Half of January

    Amarin has been rising on rumors about pharmaceutical giant Pfizer (PFE) being interested in acquiring the company.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Amarin Expects Expenses to Rise in the Future

    Amarin (AMRN) expects Vascepa to witness robust demand trends in fiscal 2019 driven by demonstrated efficacy of the drug coupled with the company’s increasing focus on creating awareness.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Amarin Is Expected to Become Profitable in Fiscal 2020

    In a press release issued on January 4, Amarin (AMRN) has announced that it will be submitting a supplemental new drug application (or sNDA) to the FDA in fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Amarin Expects Robust Revenue Growth Going Forward

    In a press release issued on January 4, Amarin (AMRN) projected net total revenues in the range of $224 million to $228 million for fiscal 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vascepa May Prove a Solid Growth Driver for Amarin Corporation

    As per Amarin’s (AMRN) investor presentation, the company aims to position Vascepa as a new treatment paradigm in the cardiovascular space.

    By Margaret Patrick
  • uploads///capsule _
    Company & Industry Overviews

    Amarin: Analysts’ Recommendations and Target Price

    Amarin is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting unmet demand in the cardiovascular space.

    By Margaret Patrick
  • uploads///UK
    Macroeconomic Analysis

    Manufacturing Production Remains Negative in the UK

    With the decline in manufacturing output, the iShares MSCI United Kingdom ETF (EWU) has fallen 6.6% over the past month as of January 12.

    By Lara Sheldon
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.